Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC Abstract #445

Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Aim(s): To compare prognostic capacity for OS and DFS of WHO, ENETS and AJCC.
Materials and methods: Patients diagnosed with small bowel, colorectal and pancreatic NETs from 1996 to 2009 in our institution, with last follow-up 30th September 2011. Kaplan-Meier analyses for OS and DFS were performed based on WHO, ENETS and AJCC. ? coefficient was calculated to evaluate the agreement between WHO, ENETS and AJCC.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dra Nuria Mulet-Margalef

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Nariman Ghaleb
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients
Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Hans-Christian Pommergaard
#2877 Comparison of Digestive and Non-Digestive Neuroendocrine Neoplasm Patient Characteristics and Survival in an ENETS Center of Excellence
Introduction: Since 2016 both digestive neuroendocrine neoplasms (D-NENs) and non-digestive NENs (ND-NENs) cases are treated within NETwerk, an ENETS Center of Excellence
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Timon Vandamme
#2886 Risk Factors for Short Recurrence-Free Survivals after Resection of PanNET Liver Metastasis: Single Institutional Analysis
Introduction: Although the treatment of PanNEN has improved survivals with development of pharmacotherapy recently, surgery is the first choice if curative resection is expected to be achieved. However, most of the patients undergo recurrence after resection of the liver metastasis even after curative resection. Therefore, it is important to identify who gains longer RFS by resection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: M.D., Ph.D. Toshihiko Masui
Authors: Masui T, Anazawa T, Nagai K, Sato A, ...